8-K Announcements
6Material company update
May 4, 2026·SEC
Material company update
Apr 14, 2026·SEC
Material company update
Feb 19, 2026·SEC
Travere Therapeutics, Inc.(TVTX)Earnings, Financials & Key Ratios
TVTX•NASDAQ
$58.85
Price updated Jun 27, 2026
AboutTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Show more
- Revenue$491M+110.5%
- EBITDA-$2M+99.3%
- Net Income-$26M+92.1%
- EPS (Diluted)-0.56+86.3%
- Gross Margin97.89%+1.3%
- EBITDA Margin-0.42%+99.6%
- Operating Margin-12.8%+90.8%
- Net Margin-5.21%+96.2%
- ROE-29.38%+88.1%
TVTX Price & Volume
Travere Therapeutics, Inc. (TVTX) stock price & volume — 10-year historical chart
Loading chart...
Sparsentan Launch Drives Revenue Amidst Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNeutral
Growth:Accelerating
Profitability:Negative
Financial Position:Strained
Cash Flow:Burning
Primary Risk:Commercial launch execution dependency
"Travere Therapeutics is currently navigating a pivotal commercial transition as the aggressive volume ramp of its lead asset, sparsentan, drives a 55.6% year-over-year revenue growth rate as of 2026Q1. While the company maintains structurally superior gross margins exceeding 98%, the path to profitability remains obscured by heavy R&D and SG&A expenditures totaling $137.4 million in the most recent quarter. Investors should monitor the company's ability to stabilize its $327.7 million debt load and manage its tightening cash runway, which declined to $78.4 million in 2026Q1."
Verdict Logic
while the 55.6% revenue growth trajectory is promising, the current cash balance of $78.4 million against a $327.7 million debt load warrants caution regarding future liquidity.
TVTX Growth Metrics
Travere Therapeutics, Inc. (TVTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years17.25%
5 Years19.87%
3 Years64.89%
TTM96.03%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM90.55%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.14%
Return on Capital
10 Years-32.91%
5 Years-47.14%
3 Years-49.16%
Last Year-14.98%
TVTX Recent Earnings
Travere Therapeutics, Inc. (TVTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 4, 2026Metric
Actual
Est
EPS
$0.39-30.0%
$0.30
Rev
$127M-6.6%
$136M
Q1 2026
Feb 19, 2026Metric
Actual
Est
EPS
$0.03+0.0%
$0.03
Rev
$130M-10.3%
$145M
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.28+190.3%
$0.31
Rev
$165M+12.2%
$147M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.14+50.0%
$0.28
Rev
$114M+15.0%
$100M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 4, 2026 | $0.39vs $0.30-30.0% | $127Mvs $136M-6.6% |
| Q1 2026 | Feb 19, 2026 | $0.03vs $0.03+0.0% | $130Mvs $145M-10.3% |
| Q4 2025 | Oct 30, 2025 | $0.28vs $0.31+190.3% | $165Mvs $147M+12.2% |
| Q3 2025 | Aug 6, 2025 | $0.14vs $0.28+50.0% | $114Mvs $100M+15.0% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Travere Therapeutics, Inc. (TVTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $58.85 | $5.47B | -105.09 | 110.45% | -5.21% | -29.38% | — | |
| $30.77 | $3.03B | -5.28 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $84.43 | $7B | 10.85 | 114.51% | -22.58% | — | — | |
| $372.25 | $10.97B | 54.42 | 33.94% | 53.92% | 19.25% | — |
Compare TVTX vs Peers
Travere Therapeutics, Inc. (TVTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TVTX SEC Filings & Documents
Travere Therapeutics, Inc. (TVTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when TVTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TVTX Frequently Asked Questions
Travere Therapeutics, Inc. (TVTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Travere Therapeutics, Inc.'s revenue?
Travere Therapeutics, Inc. (TVTX) reported $536.2M in revenue for fiscal year 2025.
How fast is Travere Therapeutics, Inc. growing?
Travere Therapeutics, Inc. (TVTX) grew revenue by 110.5% over the past year. This is strong growth.
Is TVTX profitable?
Travere Therapeutics, Inc. (TVTX) reported a net loss of $21.4M for fiscal year 2025.
Dividend & Returns
What is TVTX's return on equity?
Travere Therapeutics, Inc. (TVTX) has a return on equity (ROE) of -29.4%. Negative ROE indicates the company is unprofitable.
What is Travere Therapeutics, Inc.'s free cash flow?
Travere Therapeutics, Inc. (TVTX) generated $17.4M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.